Neuropsychopharmacology

Top Research Topics at Neuropsychopharmacology?

The journal focuses largely on the fields of Internal medicine, Neuroscience, Endocrinology, Pharmacology and Dopamine. While work presented in Neuropsychopharmacology provided substantial information on Internal medicine, it also covered topics in Placebo and Psychosis. The journal connects research in Neuroscience with the related topic of Schizophrenia.

Research in the field of Psychiatry was used to conduct the presented Schizophrenia study. The journal features Psychiatry research that overlaps with concepts in Clinical psychology. The journal holds forums on Endocrinology that merges themes from other disciplines such as Anesthesia and Antagonist.

The studies in Pharmacology featured incorporate elements of NMDA receptor, Nicotine and Opioid. Dopaminergic, Striatum, Ventral tegmental area, Dopamine receptor D2 and Amphetamine studies are all carried out as a component of the study in Dopamine presented. The majority of Serotonin studies in Neuropsychopharmacology are focused on the subject of Serotonergic.

• Internal medicine (35.30%)
• Neuroscience (31.16%)
• Endocrinology (31.01%)

What are the most cited papers published in the journal?

• Neurocircuitry of Addiction (3432 citations)
• The reward circuit: linking primate anatomy and human imaging. (2380 citations)
• Drug addiction, dysregulation of reward, and allostasis. (2307 citations)

Research areas of the most cited articles at Neuropsychopharmacology:

The most cited articles are mainly concerned with subjects like Internal medicine, Neuroscience, Endocrinology, Pharmacology and Dopamine. In addition to Internal medicine research, the journal articles aim to explore topics under Antidepressant, Placebo and Psychiatry. While Neuroscience is the focus of the published papers, it also provides insights into the studies of Psychosis and Schizophrenia.

What topics the last edition of the journal is best known for?

• Internal medicine
• Gene
• Enzyme

The previous edition focused in particular on these issues:

The journal primarily focuses on research topics in Neuroscience, Internal medicine, Prefrontal cortex, Endocrinology and Cognition. The Neuroscience study featured in the journal draws parallels with the field of Synaptic plasticity. Internal medicine research featured in the journal incorporates concerns from various other topics such as Placebo, Oncology, Depression (differential diagnoses) and Schizophrenia.

The journal explores issues in Schizophrenia which can be linked to other research areas like Bipolar disorder and Psychosis. The work tackled in the journal goes beyond the discipline of Cognition as it also encompasses Neuroimaging. Aside from discussions in Dopamine, Neuropsychopharmacology also deals with the subject of Addiction which intersects with Self-administration disciplines.

The most cited articles from the last journal are:

• Augmentation therapy with minocycline in treatment-resistant depression patients with low-grade peripheral inflammation: results from a double-blind randomised clinical trial. (28 citations)
• Big behavior: challenges and opportunities in a new era of deep behavior profiling (28 citations)
• The ABCD study: understanding the development of risk for mental and physical health outcomes. (27 citations)

Papers citation over time

A key indicator for each journal is its effectiveness in reaching other researchers with the papers published at that venue.

The chart below presents the interquartile range (first quartile 25%, median 50% and third quartile 75%) of the number of citations of articles over time.

Top authors and change over time

The top authors publishing in Neuropsychopharmacology (based on the number of publications) are:

• Trevor W. Robbins (62 papers) published 2 papers at the last edition, 1 less than at the previous edition,
• George F. Koob (57 papers) published 1 paper at the last edition the same number as at the previous edition,
• Herbert Y. Meltzer (46 papers) absent at the last edition,
• Charles B. Nemeroff (41 papers) published 2 papers at the last edition,
• Jeffrey A. Lieberman (41 papers) absent at the last edition.

The overall trend for top authors publishing in this journal is outlined below. The chart shows the number of publications at each edition of the journal for top authors.

Top affiliations and change over time

Only papers with recognized affiliations are considered

The top affiliations publishing in Neuropsychopharmacology (based on the number of publications) are:

• National Institutes of Health (425 papers) published 25 papers at the last edition, 12 more than at the previous edition,
• Yale University (327 papers) published 24 papers at the last edition, 9 more than at the previous edition,
• Harvard University (311 papers) published 42 papers at the last edition, 16 more than at the previous edition,
• Columbia University (241 papers) published 18 papers at the last edition, 7 more than at the previous edition,
• University of Pittsburgh (218 papers) published 16 papers at the last edition, 5 more than at the previous edition.

The overall trend for top affiliations publishing in this journal is outlined below. The chart shows the number of publications at each edition of the journal for top affiliations.

Publication chance based on affiliation

The publication chance index shows the ratio of articles published by the best research institutions in the journal edition to all articles published within that journal. The best research institutions were selected based on the largest number of articles published during all editions of the journal.

The chart below presents the percentage ratio of articles from top institutions (based on their ranking of total papers).Top affiliations were grouped by their rank into the following tiers: top 1-10, top 11-20, top 21-50, and top 51+. Only articles with a recognized affiliation are considered.

During the most recent 2021 edition, 1.22% of publications had an unrecognized affiliation. Out of the publications with recognized affiliations, 39.26% were posted by at least one author from the top 10 institutions publishing in the journal. Another 11.60% included authors affiliated with research institutions from the top 11-20 affiliations. Institutions from the 21-50 range included 20.74% of all publications and 28.40% were from other institutions.

Returning Authors Index

A very common phenomenon observed among researchers publishing scientific articles is the intentional selection of journals they have already attended in the past. In particular, it is worth analyzing the case when the authors participate in the same journal from year to year.

The Returning Authors Index presented below illustrates the ratio of authors who participated in both a given as well as the previous edition of the journal in relation to all participants in a given year.

Returning Institution Index

The graph below shows the Returning Institution Index, illustrating the ratio of institutions that participated in both a given and the previous edition of the conference in relation to all affiliations present in a given year.

The experience to innovation index

Our experience to innovation index was created to show a cross-section of the experience level of authors publishing in a journal. The index includes the authors publishing at the last edition of a journal, grouped by total number of publications throughout their academic career (P) and the total number of citations of these publications ever received (C).

The group intervals were selected empirically to best show the diversity of the authors' experiences, their labels were selected as a convenience, not as judgment. The authors were divided into the following groups:

• Novice - P < 5 or C < 25 (the number of publications less than 5 or the number of citations less than 25),
• Competent - P < 10 or C < 100 (the number of publications less than 10 or the number of citations less than 100),
• Experienced - P < 25 or C < 625 (the number of publications less than 25 or the number of citations less than 625),
• Master - P < 50 or C < 2500 (the number of publications less than 50 or the number of citations less than 2500),
• Star - P ≥ 50 and C ≥ 2500 (both the number of publications greater than 50 and the number of citations greater than 2500).

The chart below illustrates experience levels of first authors in cases of publications with multiple authors.

Career Prospects in Neuropsychopharmacology

Neuropsychopharmacology, with its deep integration of multiple branches such as neuroscience, pharmacology, and endocrinology, offers a myriad of exciting career opportunities in research, academia, and clinical practice. One of the potential career paths for individuals interested in clinical work related to communication and cognitive disorders is becoming a speech-language pathologist. These professionals can play a pivotal role in the multidisciplinary treatment approach by addressing various communication and swallowing problems associated with neuropsychiatric and neurodegenerative disorders. For a more detailed understanding of how to kick-start your career in this fascinating domain, you can explore this comprehensive guide on how to become a speech therapist in Alabama. Apart from this, those with strong interests in research can also look forward to working as a research scientist, focusing on pivotal areas such as synaptic plasticity, dopamine and serotonin research, and neurocircuitry of addiction. Academia also provides an avenue to apply this knowledge and contribute to the training and education of future researchers and clinicians. Regardless of the chosen path, career prospects in neuropsychopharmacology remain strong, leveraging the continual advancements in our understanding and treatment of the human brain and mind.